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Complement is a critical system of enzymes, regulatory proteins, and receptors that regu-
lates both innate and adaptive immune responses. Natural mutations in complement mol-
ecules highlight their requirement in regulation of a variety of human conditions including
infectious disease and autoimmunity. As sentinels of the immune system, macrophages
are specialized to respond to infectious microbes, as well as normal and altered self, and
dictate appropriate immune responses. Complement components such as anaphylatoxins
(C3a and C5a) and opsonins [C3b, C1q, mannan binding lectin (MBL)] influence macrophage
responses. While anaphylatoxins C3a and C5a trigger inflammasome activation, opsonins
such as C1q and related molecules (MBL and adiponectin) downregulate inflammasome
activation and inflammation, and upregulate engulfment of apoptotic cells consistent with
a pro-resolving or M2 macrophage phenotype. This review summarizes our current under-
standing of the influence of the complement system on macrophage polarization with an
emphasis on C1q and related molecules.
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COMPLEMENT SYSTEM
The complement system comprises over 35 cell associated and sol-
uble molecules, which play a critical role in our innate immune
response. Activation of complement begins with a recognition
step. Recognition proteins of the complement system include C1q,
mannan binding lectin (MBL), and ficolins (ficolin-1, -2, -3).
These proteins are innate pattern recognition receptors (PRRs)
and are capable of recognizing a wide range of structures includ-
ing foreign organisms, either via binding directly to their pathogen
associated molecular patterns (PAMPs) or when coated with anti-
body in an immune-complex (C1q) [reviewed in Ref. (1)]. In addi-
tion, these PRRs also recognize and bind to structures associated
with cellular damage/debris such as apoptotic cell associated mol-
ecular patterns (ACAMPs) like phosphatidylserine, damage asso-
ciated molecular patterns (DAMPs) like oxidation neo-epitopes,
and fibrillar protein structures (2–8). Activation of complement
via the classical pathway (C1q), lectin pathway (MBL/ficolins),
or alternative pathway (C3 “tickover” autoactivation/properdin)
begins a coordinated cascade of enzymatic cleavage events gen-
erating complement protein fragments that carry out effector
functions. These include opsonization for enhanced phagocytosis,
either directly or via production of C3b, triggering inflammation
through production of anaphylatoxins C3a and C5a, and lysis of
target cells through deposition of C5b-9, the membrane attack
complex (MAC), in the complement terminal pathway (Figure 1).
COMPLEMENT DEFICIENCIES IN HUMAN DISEASE
Genetic deficiencies in complement components highlight its
important role not only in clearance of pathogens but also in
removal of dying cells/cellular debris and prevention of autoim-
munity. For example, genetic deficiencies in lectin, alternative and
terminal pathway components like MBL, factor D, properdin, C3,
C5, C6, C7, C8, and C9, increase susceptibility to infections, in
particular, by encapsulated bacteria [reviewed in Ref. (9)]. The
strong link between late complement component deficiencies (C5–
9) and recurrent neisserial infections indicates a critical role for
C5b–9 MAC deposition in direct bactericidal defense. However,
deficiency in early classical pathway component C1q is strongly
associated with development of the autoimmune disease systemic
lupus erythematosus (SLE), likely due to impaired opsonophago-
cytosis, and compromised removal of immune complexes and
apoptotic cells [reviewed in Ref. (10)]. Weaker associations with
SLE are also seen with deficiencies in other classical pathway com-
ponents C1r/s, C2, C4, and C3. Thus, complement opsonization
via C1q recognition plays a critical role in maintaining normal tis-
sue homeostasis and prevention of autoimmunity. While excessive
or inappropriate complement activation is associated with almost
all inflammatory or inflammation-related diseases including can-
cer, Alzheimer’s disease (AD), and metabolic disease [reviewed in
Ref. (11, 12)], associations of these diseases with (generally very
rare) complement deficiencies in humans have not been reported.
However, polymorphisms in MBL2 are common, and provide
extensive evidence for links between MBL levels and cardiovascular
disease [reviewed in Ref. (13)].
COMPLEMENT RECEPTORS ON MACROPHAGES
Macrophages are key players in carrying out complement effec-
tor functions. Complement components including C1q, MBL,
C3b, C4b, C3a, and C5a interact with a variety of receptors
on macrophages, leading to modulation of cytokine produc-
tion/inflammatory responses and increased opsonophagocytic
clearance of targets. For example, monocytes and macrophages
www.frontiersin.org August 2014 | Volume 5 | Article 402 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bohlson et al. Complement-dependent macrophage polarization
FIGURE 1 |The interaction of macrophages with complement. Innate
immune pattern recognition receptors C1q, MBL, and ficolins recognize a
number of structures including immune complexes, damaged-self molecules
expressing damage associated molecular patterns (DAMPS), apoptotic cells
(ACAMPs), and pathogens (PAMPs), leading to activation of classical and
lectin pathways, respectively, and amplification via the alternative pathway.
Complement activation has three main effector functions: cytolysis via
membrane attack complex (MAC) formation, inflammation mediated by
anaphylatoxins C3a and C5a, and opsonization leading to phagocyte clearance
via C3b deposition. However, C1q, MBL, and ficolins also have non-cascade
activation related functions and are directly opsonic, leading to enhanced
clearance of targets and phagocyte activation. Macrophages express a
number of receptors that recognize complement components. The gC1qR
and cC1qR bind the globular heads and collagen-like tail domains of C1q,
respectively. However, additional C1q receptors likely exist (C1qR), some of
which may also recognize the closely related collagen-like domains of other
defense collagen family members, MBL and ficolins. Additional complement
receptors on macrophages CR1, CR3, CR4, and CRIg recognize
C3b-opsonized targets either as intact C3b or its degradation fragment iC3b.
Macrophages also express receptors for complement activation fragments
C3a (C3aR) and C5a (C5aR1 and C5aR2). Thus, macrophages are key players
in carrying out the effector functions of complement activation.
express complement receptors CR1 (CD35), CR3 (CD11b/CD18),
and CR4 (CD11c/CD18). CR1 binds complement opsonins C1q,
C3b, and C4b, which are deposited on target cells/surfaces (14)
and reviewed in Ref. (15). Binding to CR1 promotes phagocy-
tosis of targets, along with degradation of C3b to its inactive
fragment iC3b, preventing C5-convertase activity and thus inhibit-
ing the complement terminal pathway. CR3 and CR4 bind iC3b
and promote the phagocytosis of targets. Genetic deficiencies
in these receptors are also a risk factor for the development of
SLE [reviewed in Ref. (10, 16)]. A subset of tissue macrophages
expresses the complement receptor CRIg. Gene expression of this
receptor is associated with activated macrophages (17), and the
protein is found in human liver Kupffer cells and in subsets
of various resident tissue macrophages including alveolar and
synovial macrophages (18). CRIg binds to C3b, and its degra-
dation product, iC3b, and was shown to be important in clearance
of C3b-opsonized pathogens from the circulation.
Beyond CR1, macrophages express other receptors capable of
binding C1q. These include the ubiquitously co-expressed mol-
ecules gC1qR and cC1qR. gC1qR binds to the globular heads of
C1q (19), whereas cC1qR (calreticulin) interacts with both the
collagen-like tail and globular head domains of C1q (4). C1q
opsonized targets are internalized more rapidly than in the absence
of C1q via interaction of the collagen-like tail with a receptor on
phagocytes (20). In addition, C1q bound to a variety of targets
modulates macrophage inflammatory responses via its collagen-
like domain (5, 21). The collagen-like domain of C1q is a feature
shared with other so-called “defense collagens.” This family of
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molecules includes MBL and ficolins, which also trigger enhanced
phagocytosis [reviewed in Ref. (1)] and modulate cytokine pro-
duction (22). While the phagocytic receptor is not definitively
identified for all targets, involvement of the cC1qR has been impli-
cated in the C1q- and MBL-mediated removal of apoptotic cells
by macrophages (6). An additional family of proteins, termed
C1q/TNF-related proteins (CTRPs), contains C-terminal globu-
lar domains homologous to C1q (23, 24). Adiponectin is perhaps
the best characterized member of the CTRP family, and inter-
acts with macrophages, regulating inflammatory responses similar
to C1q (25). However, the receptors for the metabolic actions of
adiponectin were shown to be distinct from the C1qR, and include
AdipoR1 and AdiopR2 (26).
COMPLEMENT ANAPHYLATOXINS
Complement anaphylatoxins C3a and C5a are soluble complement
fragments produced from C3 or C5 by activation of the C3- or
C5-convertase enzyme complex, respectively. They carry out their
biological functions via interactions with three receptors. These
include the C3a receptor (C3aR) (27), which binds C3a but not its
degradation product C3a-desArg, the C5a receptor (C5aR1) (28),
which binds C5a, and C5a receptor-like 2 (C5aR2, C5L2) (29),
which binds C5a but has greater affinity for C5a-desArg. C5aR2
lacks signaling capabilities (30), and thus, is considered a decoy
receptor, capable of sequestering the bioavailability of C5a/C5a-
desArg and limiting their ability to activate via the C5aR1. C5aR2
may also bind C3a-desArg, but this is controversial (31). Cellular
expression of the anaphylatoxin receptors is widespread but partic-
ularly includes immune cells like monocytes and macrophages (32,
33). Interestingly, LPS, associated with M1 macrophage polariza-
tion increases gene expression of C5aR1 in macrophages (34) while
IL-4, associated with M2 macrophage polarization downregulates
C5aR1 expression (35).
MACROPHAGE POLARIZATION
Macrophages are grouped as M1 and M2 in accordance with
the Th1/Th2 nomenclature, and this terminology describes two
macrophage phenotypes: the pro-inflammatory/classically acti-
vated macrophage (M1) and the pro-resolving/alternatively acti-
vated macrophage (M2). The expression of a variety of genes
has been associated with macrophage polarization, most notably,
the machinery required for enzymatic breakdown of arginine in
pro-resolving and pro-inflammatory macrophages. By expressing
arginase, pro-resolving macrophages generate ornithine, which
promotes proliferation and repair, whereas pro-inflammatory
(M1) macrophages express inducible nitric oxide synthase and
generate nitric oxide (NO), an important molecule in host defense
against invading pathogens, which also inhibits cell prolifera-
tion [reviewed in Ref. (36)]. Intermediates in the two enzymatic
pathways act antagonistically, inhibiting the other when they are
activated (37). Consistent with a role in promotion of inflamma-
tion, M1 macrophages are also often associated with an increased
production of pro-inflammatory cytokines such as TNFα and IL-
1β. In contrast, M2 macrophages, which are pro-resolving, are
often associated with increased production of anti-inflammatory
cytokine IL-10.
Although the idea of macrophages having separate pheno-
types is helpful in defining their action, it is also somewhat
misleading and over simplified. In vivo, macrophages are con-
stantly encountering various external signals leading to a very
fluid existence in terms of phenotypes (38). Even within the same
site and population, macrophages can express different and con-
stantly changing phenotypes, termed macrophage plasticity (39).
Macrophage polarization is a result of a combination of exter-
nal signals macrophages receive from their environment. Com-
mon signals that have been investigated include the Th1 cytokine
interferon-γ (IFN-γ) and various PAMPs, which are associated
with M1 polarization and the Th2 cytokines IL-4/IL-13, which are
associated with M2 polarization. Here, we will review some recent
work illuminating the role of the complement system in regulating
macrophage activation and polarization.
COMPLEMENT ANAPHYLATOXINS REGULATE MACROPHAGE
ACTIVATION
Complement anaphylatoxins, C3a and C5a, are pro-inflammatory
and trigger monocyte and macrophage activation through vari-
ous signaling mechanisms. For example, upon LPS stimulation
in human monocytes, C3a induces NLRP3 inflammasome activa-
tion through an increase in ATP release mediated by extracellular
signal-regulated kinase 1/2 (ERK1/2) (40). Samstad et al. found
that C5a produced during complement activation by cholesterol
crystals, influenced inflammation through NLRP3 inflammasome
activation and IL-1β and TNFα release, and increased the produc-
tion of reactive oxygen species (ROS) (41). C5a was also correlated
with IL-6 induction and development of inflammatory T-helper
17 cells (42), as well as affecting IL-17 and IL-23 production
(43). Interestingly, sublethal MAC (C5b-9) deposition rather than
C3a or C5a was demonstrated to trigger inflammasome activa-
tion in murine dendritic cells following LPS stimulation (44). In
the CNS, C5a provides a chemotactic and activation signal for
microglia and astrocytes [reviewed in Ref. (45)]. It can also syn-
ergize with damage signals such as amyloid beta (Aβ) to trigger
enhanced inflammatory cytokine production (46). Thus, activa-
tion of complement by extracellular Aβ plaques can exacerbate
inflammation and may play a substantial role in the pathogene-
sis of AD. Indeed, treatment with a C5a receptor antagonist was
shown to decrease deposition of fibrillar Aβ and inflammatory glia
and improve cognitive performance in mice models of AD (47).
Many other diseases are associated with anaphylatoxin signaling,
including allergic, infectious, autoimmune diseases, and cancer
(48). Clearly, the pro-inflammatory signaling provided by the ana-
phylatoxins contributes to both beneficial (pathogen clearing) and
detrimental (inflammatory disease-related) inflammation.
COMPLEMENT OPSONINS REGULATE MACROPHAGE
ACTIVATION
C3b-MEDIATED OPSONIZATION
One of the major effector functions of the complement sys-
tem is the tagging, or opsonization, of pathogens and/or cellular
debris for clearance by phagocytes. Complement component C3
is the most abundant complement component in blood at about
1.2 mg/ml, and as such, permissible surfaces become readily coated
in C3b and iC3b following cleavage of C3. CR3 is a major phago-
cytic receptor expressed on macrophages that is involved in clear-
ance of iC3b opsonized particles (Figure 1). In contrast to other
phagocytic receptors such as Fcγ receptors, engulfment of iC3b
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coated particles via CR3 has traditionally been considered anti-
inflammatory. For example, CR3-dependent engulfment does not
activate the arachidonic acid cascade (49) or the release of toxic
oxygen products (50). In early experiments assessing macrophage
heterogeneity, Stein and colleagues demonstrated increased secre-
tion of TNFα from macrophages elicited into the peritoneal cavity
by inflammatory mediators (e.g., thioglycollate) when compared
to resident peritoneal macrophages. However, independent of the
macrophage phenotype, all macrophages failed to secrete signifi-
cant levels of TNFα following ligation of CR3 whereas ligation of
Fcγ receptors led to TNFα release by all macrophage subsets (51).
In studies with the macrophage intracellular pathogen Mycobac-
terium avium, C3-independent phagocytosis of M. avium resulted
in enhanced TNFα production (52, 53). More recent reports
assessing pathogenesis of Francisella tularensis support a role
for CR3 in inducing immune suppression and facilitating infec-
tion with this intracellular pathogen (54). While CR3-dependent
immune suppression is detrimental in the course of F. tularensis
infection or other infectious disease processes, it is beneficial in
the context of clearance of apoptotic cells and/or cellular debris.
COMPLEMENT-DEPENDENT ENGULFMENT OF APOPTOTIC CELLS
Complement components readily coat the surface of apoptotic
cells and facilitate ingestion by macrophages (55, 56). Ingestion
of apoptotic cells is a silent process accompanied by the pro-
duction of anti-inflammatory cytokines TGFβ and IL-10 (57).
Complement mediated opsonization of apoptotic cells is largely
dependent on the classical complement pathway, and deficien-
cies in early components of the classical pathway (C1q, C4, and
C2) result in inefficient disposal of apoptotic cells and subse-
quent autoimmunity (58–60). While C1q deficiency results in
development of lupus in virtually all cases, absence of C3, C2,
and C4 results in lupus at lower frequency indicating a role for
C1q beyond classical complement pathway activation in regula-
tion of the immune response (61). Recent reports have indicated
that C1q regulates the monocyte/macrophage/dendritic cell phe-
notype leading to development of a phagocyte that is specialized
to resolve inflammation. Specifically, the C1q-stimulated phago-
cyte is pro-efferocytic and anti-inflammatory (Figure 2). As such,
complement opsonins are mediating activity beyond the imme-
diate stimulation of enhanced phagocytosis; they are inducing
a macrophage phenotype, or polarizing macrophages toward a
pro-resolving phenotype. This would be consistent with obser-
vation that C1q deficiency results in autoimmunity and chronic
inflammation.
Korb and Ahearn were the first to describe a role for C1q in the
clearance of apoptotic cells, and suggested that C1q-dependent
engulfment of apoptotic cells was important in prevention of
autoimmunity in lupus (62). There has been wide support for
this hypothesis, and Bhatia et al. demonstrated that removal of
apoptotic cells by C1q was also important in prevention of the
inflammatory disease atherosclerosis (63). However, the recep-
tors/signal transduction pathway leading to C1q-dependent effe-
rocytosis has not been clearly delineated [reviewed in Ref. (56)].
C1q binds to apoptotic cells and serves as a bridging molecule link-
ing the apoptotic cell to the phagocyte via calreticulin (cC1qR)
and its binding partner, the phagocytic receptor LRP (CD91)
FIGURE 2 | Complement regulates macrophage polarization. In culture,
M1 macrophages (inflammatory, pathogen clearing) are induced by IFNγ or
PAMPs and are characterized by production of iNOS and pro-inflammatory
cytokines such as TNFα and IL-1β. M2 macrophages (resolving, apoptotic
cell and damaged molecule clearing) are induced by IL-4 and characterized
by arginase and anti-inflammatory cytokine IL-10 production. Complement
components C3a, C5a, and C5b-9 modulate cytokine production in
macrophages toward an inflammatory (M1-like) phenotype. Apoptotic cells
and targets opsonized with complement components C1q or C3b increase
clearance and modulate cytokine production in macrophages toward an
anti-inflammatory, resolving (M2-like) phenotype and can block
PAMP-mediated pro-inflammatory signaling. Thus, complement plays a dual
role in macrophage activation and polarization depending on the target.
(6). However, macrophages deficient in LRP still respond to C1q
with enhanced phagocytosis and efferocytosis indicating that there
are multiple mechanisms of C1q-dependent engulfment (64). We
demonstrated that mouse bone marrow derived macrophages and
peritoneal macrophages stimulated with C1q upregulated expres-
sion of engulfment machinery including Mer tyrosine kinase and
the MerTK ligand Gas6, leading to development of a macrophage
that is primed for efferocytosis (65). More recently, we showed that
this pathway is shared with a C1q homolog, adiponectin (66) and
not with MBL, a C1q-related collectin (65).
C1q AND ADIPONECTIN MEDIATE EFFEROCYTOSIS VIA A SHARED
PATHWAY
Adiponectin is referred to as an adipokine; it is produced by
adipocytes and is secreted into circulation where it modulates
biological responses via several receptors including adiponectin
receptor 1 (AdipoR1), adiponectin receptor 2 (AdipoR2), or
T cadherin (T-cad) (67, 68). More recent studies have sug-
gested there is an additional receptor on macrophages that medi-
ates adiponectin signaling; however, this receptor has not been
identified (69). Adiponectin signaling leads to activation of 5′
adenosine monophosphate-activated protein kinase (AMPK) and
peroxisome proliferator-activated receptor alpha (PPARα), and
adiponectin-dependent regulation of metabolism is mediated via
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these key signaling nodes (70). Much information has been gath-
ered regarding the role of AMPK in the regulation of metabolic
activity; however, recent studies suggest that AMPK also influences
the immune response, including macrophage cytokine expres-
sion and phagocytosis. For example, silencing of AMPK inhibits
LPS- and fatty acid-mediated inflammation in macrophages
(71). In addition, AMPK activation is associated with enhanced
phagocytosis and efferocytosis, as well as macrophage polariza-
tion (72, 73). Similarly, C1q stimulates enhanced phagocyto-
sis and diminution of pro-inflammatory cytokine production
from myeloid cells, and we recently demonstrated that C1q and
adiponectin-dependent Mer expression and efferocytosis require
activation of AMPK (66). These studies have begun to define
the mechanism by which C1q and related opsonins modulate
macrophage activation.
C1q AND MBL INHIBIT PRO-INFLAMMATORY AND PROMOTE
ANTI-INFLAMMATORY CYTOKINE PRODUCTION
In line with these observations, Fraser and colleagues demon-
strated that both C1q-stimulated human monocytes and C1q-
stimulated mouse microglia produce increased anti-inflammatory
IL-10 and decreased pro-inflammatory cytokines following stim-
ulation with the TLR4 ligand LPS (21, 22). Similar activity was
shown for MBL indicating that this is a distinct mechanism
for macrophage activation, independent of AMPK-mediated Mer
expression since MBL failed to upregulate Mer-dependent effero-
cytosis. C1q/MBL-dependent activation of NFκB p50p50 homod-
imers were suggested to contribute to the anti-inflammatory phe-
notype via competitive inhibition of pro-inflammatory NFκB
p50p65 heterodimer activation and/or via transcriptional acti-
vation of IL-10 (74). The same group demonstrated that C1q
promoted M2 polarization and limited inflammasome activa-
tion in human monocyte derived macrophages (75). Interferon-
alpha (IFN-α) is a pro-inflammatory cytokine that contributes
to dendritic cell activation, a breakdown in peripheral toler-
ance and autoimmunity (76). C1q modulates IFN-α produc-
tion from human phagocytes in response to a variety of stim-
uli (75, 77, 78). Santer and colleagues demonstrated that C1q
deficiency in human lupus patients resulted in elevated IFN-
α levels in serum and cerebrospinal fluid, and that C1q sup-
pressed immune-complex stimulated IFN-α production from
human monocytes (78–80). The anti-inflammatory effects of
C1q are not limited to apoptotic cells. C1q has also been
shown to enhance the uptake of atherogenic forms of lipopro-
teins such as oxidized or acetylated LDL (oxLDL, AcLDL)
(81). During clearance of oxLDL by macrophages, C1q also
modulates cytokine production toward an anti-inflammatory,
resolving phenotype and dampens transcriptional activity by
p50/p65 NFκB heterodimers, which may be important in lim-
iting inflammation in the early atherosclerotic lesion (82).
Combined, these data further support the hypothesis that
C1q programs macrophages toward an anti-inflammatory, pro-
efferocytic/phagocytic phenotype. Future studies should delin-
eate the relative activity of C1q-dependent constitutive effe-
rocytosis/phagocytosis versus programed polarization in the
contribution toward protection from autoimmune and inflam-
matory disease.
CONCLUDING REMARKS
The complement system has traditionally been considered an arm
of the innate immune response required for promotion of inflam-
mation and pathogen clearance. While these functions of comple-
ment are essential to host defense, more recent advances demon-
strate a novel role for components of the complement system
in resolution of inflammation and protection from autoimmune
and inflammatory diseases including SLE, neurodegenerative dis-
ease, and atherosclerosis. In particular, complement component
C1q directs macrophage polarization leading to generation of
pro-resolving macrophages that promote clearance of apoptotic
cells with diminished pro-inflammatory cytokine production and
increased anti-inflammatory cytokine production. C1q is synthe-
sized by macrophages in response to tissue injury and is likely to
be an important signal in resolution of inflammation independent
of other complement components. Moreover, C1q-related mole-
cules such as the complement component MBL, and the adipokine
adiponectin, also downregulate macrophage-mediated inflam-
matory responses and upregulate efferocytosis. Identification of
the molecular mechanisms by which these molecules govern
macrophage activation, as well as their relative contribution to dis-
ease resolution, should reveal pathways to target for development
of novel therapeutics in autoimmune and inflammatory disease.
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